Abstract:Highlights • The immune response and inflammation in pulmonary hypertension (PH) have been systematically summarized based on recent studies. • The relationship between CC chemokines and the pathogenesis of PH is summarized in clinical and animal models. • We found that although the immune response serves as an important potential factor in the pathogenesis of PH, less attention has been paid to CC chemokines and their receptors. • We believe that a greater understanding of the relationship between PH and CC chemokines and their receptors is a pressing issue. • We believe that we need to further clarify the pathogenesis of PH and provide basis for the clinical treatment of PH. Background Pulmonary hypertension (PH) represents a progressive condition characterized by the remodeling of pulmonary arteries, ultimately culminating in right heart failure and increased mortality rates. Substantial evidence has elucidated the pivotal role of perivascular inflammatory factors and immune dysregulation in the pathogenesis of PH. Chemokines, a class of small secreted proteins, exert precise control over immune cell recruitment and functionality, particularly with respect to their migration to sites of inflammation. Consequently, chemokines emerge as critical drivers facilitating immune cell infiltration into the pulmonary tissue during inflammatory responses. This review comprehensively examines the significant contributions of CC chemokines in the maintenance of immune cell homeostasis and their pivotal role in regulating inflammatory responses. The central focus of this discussion is directed towards elucidating the precise immunoregulatory actions of CC chemokines concerning various immune cell types, including neutrophils, monocytes, macrophages, lymphocytes, dendritic cells, mast cells, eosinophils, and basophils, particularly in the context of PH processes. Furthermore, this paper delves into an exploration of the underlying pathogenic mechanisms that underpin the development of PH. Specifically, it investigates processes such as cellular pyroptosis, examines the intricate crosstalk between bone morphogenetic protein receptor type 2 (BMPR2) mutations and the immune response, and sheds light on key signaling pathways involved in the inflammatory response. These aspects are deemed critical in enhancing our understanding of the complex pathophysiology of PH. Moreover, this review provides a comprehensive synthesis of findings from experimental investigations targeting immune cells and CC chemokines. Aim of review :In summary, the inquiry into the inflammatory responses mediated by CC chemokines and their corresponding receptors, and their potential in modulating immune reactions, holds promise as a prospective avenue for addressing PH. The potential inhibition of CC chemokines and their receptors stands as a viable strategy to attenuate the inflammatory cascade and ameliorate the pathological manifestations of PH. Nonetheless, it is essential to acknowledge the current state of clinical trials and the ensuing progress, which regrettably appears to be less than encouraging. Substantial hurdles exist in the successful translation of research findings into clinical applications. The intention is that such emphasis could potentially foster the advancement of potent therapeutic agents presently in the process of clinical evaluation. This, in turn, may further bolster the potential for effective management of PH. Graphical abstract Download : Download high-res image (160KB) Download : Download full-size image

Innovative Anti-Inflammatory and Pro-resolving Strategies for Pulmonary Hypertension: High Blood Pressure Research Council of Australia Award 2019

Epigenetic Regulation and Its Therapeutic Potential in Pulmonary Hypertension

Epigenetic Modulation in the Initiation and Progression of Pulmonary Hypertension.

Abstract 14566: the Role of Eosinophils in Pulmonary Hypertension

The Role of Immune Cells and Inflammation in Pulmonary Hypertension: Mechanisms and Implications

Dysregulated Immunity in Pulmonary Hypertension: From Companion to Composer

Immunotherapy for Pulmonary Arterial Hypertension: From the Pathogenesis to Clinical Management

Pyroptosis, apoptosis, necroptosis and endoplasmic reticulum stress in pulmonary hypertension

Resolution of inflammation, an active process to restore the immune microenvironment balance: A novel drug target for treating arterial hypertension

Immunity and Inflammation in Pulmonary Arterial Hypertension: From Pathophysiology Mechanisms to Treatment Perspective

Pathology and pathobiology of pulmonary hypertension: current insights and future directions

Novel insights and new therapeutic potentials for macrophages in pulmonary hypertension

Vasoactive peptides and the pathogenesis of pulmonary hypertension: role and potential therapeutic application

Identification of immune‐associated signatures and potential therapeutic targets for pulmonary arterial hypertension

Ultrasound Neuromodulation of an Anti-Inflammatory Pathway at the Spleen Improves Experimental Pulmonary Hypertension

Mechanisms and treatment of pulmonary arterial hypertension

Emerging pharmacotherapies for the treatment of pulmonary arterial hypertension

The inflammatory cell landscape in the lungs of patients with idiopathic pulmonary arterial hypertension

Pulmonary Hypertension: Pharmacological and Non-Pharmacological Therapies

Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives

Immunoregulatory macrophages modify local pulmonary immunity and ameliorate hypoxic-pulmonary hypertension